IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes.
The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more
